Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 16, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 19, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001209181-26-000007
Filed / recorded
Sep 19, 2026, 3:01 AM UTC
Added to OQRO
Oct 6, 2026, 8:46 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Roivant Sciences Ltd.
Issuer CIK
1635088
Ticker
ROIV
Reporting person
James C Momtazee
Relationship
Director
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Sep 16, 2026
Transaction code
A
Shares / units
10,531
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
10,531
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.